Search
Mubodina
go.drugbank.com/drugs/DB17616ExperimentalIt was investigated in various conditions including primary membranoproliferative glomerulonephritis and typical hemolytic uremic syndrome. … Mubodina is an investigational drug developed by Adienne Pharma & Biotech. It is a recombinant human minibody directed against complement component C5.
ZUBERITAMAB
go.drugbank.com/drugs/DB19443InvestigationalZuberitamab is under investigation in clinical trial NCT06642909 (A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy).
Menaquinone 7
go.drugbank.com/drugs/DB13075InvestigationalMenaquinone 7 is under investigation in clinical trial NCT00402974 (The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children).
Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10774ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10775ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10780ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10781ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10782ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10792ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Bolivia/559/2013 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB11034ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.